These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 33128595)

  • 1. Immune checkpoint inhibition in upper tract urothelial carcinoma.
    Califano G; Ouzaid I; Verze P; Hermieu JF; Mirone V; Xylinas E
    World J Urol; 2021 May; 39(5):1357-1367. PubMed ID: 33128595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors for urothelial carcinoma.
    Kim HS; Seo HK
    Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
    Rouprêt M; Seisen T; Birtle AJ; Capoun O; Compérat EM; Dominguez-Escrig JL; Gürses Andersson I; Liedberg F; Mariappan P; Hugh Mostafid A; Pradere B; van Rhijn BWG; Shariat SF; Rai BP; Soria F; Soukup V; Wood RG; Xylinas EN; Masson-Lecomte A; Gontero P
    Eur Urol; 2023 Jul; 84(1):49-64. PubMed ID: 36967359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
    Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
    Pham MN; Apolo AB; De Santis M; Galsky MD; Leibovich BC; Pisters LL; Siefker-Radtke AO; Sonpavde G; Steinberg GD; Sternberg CN; Tagawa ST; Weizer AZ; Woods ME; Milowsky MI
    World J Urol; 2017 Mar; 35(3):367-378. PubMed ID: 27342991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma.
    Inokuchi J; Eto M
    Cancer Manag Res; 2019; 11():4519-4528. PubMed ID: 31191013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
    Koshkin VS; Grivas P
    Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
    Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
    J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urothelial carcinoma in the era of immune checkpoint inhibitors.
    Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
    Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of immunotherapy targeting the PD-1 pathway for advanced urothelial carcinoma: a meta-analysis of published clinical trials.
    Zhang F; Liu Z; Liang J; Zhang F; Wu K; Zhou C; Lu Y; Wang X
    Clin Transl Oncol; 2020 Oct; 22(10):1750-1761. PubMed ID: 32086783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab for the treatment of urothelial carcinoma.
    Alsharedi M; Srivastava R; Elmsherghi N
    Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma.
    Ghatalia P; Plimack ER
    J Natl Compr Canc Netw; 2020 Mar; 18(3):355-361. PubMed ID: 32135514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
    Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
    Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
    Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
    Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
    Nishiyama N; Kita Y; Ito K; Kato M; Hatakeyama S; Matsushita Y; Naito S; Miyake M; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Nishiyama H; Kobayashi T; Kitamura H;
    Anticancer Res; 2023 Nov; 43(11):5041-5050. PubMed ID: 37909969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zacharis A; Grüllich C
    Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma.
    Okuda Y; Kato T; Fujita K; Fushimi H; Miyamoto H; Netto GJ; Nonomura N
    Cancer Genomics Proteomics; 2024; 21(2):137-143. PubMed ID: 38423597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
    Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
    Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.